ID   PCKGC_RAT               Reviewed;         622 AA.
AC   P07379;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1988, sequence version 1.
DT   29-MAY-2024, entry version 190.
DE   RecName: Full=Phosphoenolpyruvate carboxykinase, cytosolic [GTP] {ECO:0000305};
DE            Short=PEPCK-C;
DE            EC=4.1.1.32 {ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:26709450, ECO:0000269|PubMed:28345895, ECO:0000269|PubMed:30193097, ECO:0000269|PubMed:31461616};
DE   AltName: Full=Serine-protein kinase PCK1 {ECO:0000305};
DE            EC=2.7.11.- {ECO:0000250|UniProtKB:P35558};
GN   Name=Pck1 {ECO:0000303|PubMed:24863970, ECO:0000312|RGD:3267};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   PubMed=2993287; DOI=10.1016/s0021-9258(19)85145-1;
RA   Beale E.G., Chrapkiewicz N.B., Scoble H.A., Metz R.J., Quick D.P.,
RA   Noble R.L., Donelson J.E., Biemann K., Granner D.K.;
RT   "Rat hepatic cytosolic phosphoenolpyruvate carboxykinase (GTP). Structures
RT   of the protein, messenger RNA, and gene.";
RL   J. Biol. Chem. 260:10748-10760(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 279-290, AND ACTIVE SITE.
RC   TISSUE=Liver;
RX   PubMed=2909519; DOI=10.1016/s0021-9258(17)31219-x;
RA   Lewis C.T., Seyer J.M., Carlson G.M.;
RT   "Cysteine 288: an essential hyperreactive thiol of cytosolic
RT   phosphoenolpyruvate carboxykinase (GTP).";
RL   J. Biol. Chem. 264:27-33(1989).
RN   [4]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=4186849; DOI=10.1016/s0021-9258(18)63606-3;
RA   Ballard F.J., Hanson R.W.;
RT   "Purification of phosphoenolpyruvate carboxykinase from the cytosol
RT   fraction of rat liver and the immunochemical demonstration of differences
RT   between this enzyme and the mitochondrial phosphoenolpyruvate
RT   carboxykinase.";
RL   J. Biol. Chem. 244:5625-5630(1969).
RN   [5]
RP   INDUCTION.
RX   PubMed=6096365; DOI=10.1016/s0021-9258(17)42541-5;
RA   Sasaki K., Cripe T.P., Koch S.R., Andreone T.L., Petersen D.D., Beale E.G.,
RA   Granner D.K.;
RT   "Multihormonal regulation of phosphoenolpyruvate carboxykinase gene
RT   transcription. The dominant role of insulin.";
RL   J. Biol. Chem. 259:15242-15251(1984).
RN   [6]
RP   INDUCTION.
RX   PubMed=18335579; DOI=10.1055/s-2007-1004526;
RA   Christ B.;
RT   "Inhibition of glucagon-signaling and downstream actions by interleukin
RT   1beta and tumor necrosis factor alpha in cultured primary rat
RT   hepatocytes.";
RL   Horm. Metab. Res. 40:18-23(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19 AND SER-118, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [8]
RP   FUNCTION, PATHWAY, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   ACTIVITY REGULATION, ACETYLATION AT LYS-91; LYS-473; LYS-521 AND LYS-524,
RP   PHOSPHORYLATION, AND MUTAGENESIS OF SER-90 AND LYS-91.
RX   PubMed=30193097; DOI=10.1016/j.molcel.2018.07.031;
RA   Latorre-Muro P., Baeza J., Armstrong E.A., Hurtado-Guerrero R., Corzana F.,
RA   Wu L.E., Sinclair D.A., Lopez-Buesa P., Carrodeguas J.A., Denu J.M.;
RT   "Dynamic acetylation of phosphoenolpyruvate carboxykinase toggles enzyme
RT   activity between gluconeogenic and anaplerotic reactions.";
RL   Mol. Cell 71:718-732(2018).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF APOENZYME AND IN COMPLEX WITH
RP   MANGANESE; GTP AND SUBSTRATE, COFACTOR, SUBUNIT, AND REACTION MECHANISM.
RX   PubMed=17685635; DOI=10.1021/bi701038x;
RA   Sullivan S.M., Holyoak T.;
RT   "Structures of rat cytosolic PEPCK: insight into the mechanism of
RT   phosphorylation and decarboxylation of oxaloacetic acid.";
RL   Biochemistry 46:10078-10088(2007).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH MANGANESE AND
RP   SUBSTRATE ANALOG, COFACTOR, AND SUBUNIT.
RX   PubMed=18197707; DOI=10.1021/bi7020662;
RA   Stiffin R.M., Sullivan S.M., Carlson G.M., Holyoak T.;
RT   "Differential inhibition of cytosolic PEPCK by substrate analogues. Kinetic
RT   and structural characterization of inhibitor recognition.";
RL   Biochemistry 47:2099-2109(2008).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF APOENZYME AND IN COMPLEX WITH
RP   MANGANESE; GTP AND SUBSTRATE, COFACTOR, SUBUNIT, AND REACTION MECHANISM.
RX   PubMed=18772387; DOI=10.1073/pnas.0805364105;
RA   Sullivan S.M., Holyoak T.;
RT   "Enzymes with lid-gated active sites must operate by an induced fit
RT   mechanism instead of conformational selection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:13829-13834(2008).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) IN COMPLEX WITH MANGANESE; GTP AND
RP   SUBSTRATES, COFACTOR, AND SUBUNIT.
RX   PubMed=20476774; DOI=10.1021/bi100399e;
RA   Johnson T.A., Holyoak T.;
RT   "Increasing the conformational entropy of the Omega-loop lid domain in
RT   phosphoenolpyruvate carboxykinase impairs catalysis and decreases catalytic
RT   fidelity.";
RL   Biochemistry 49:5176-5187(2010).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.20 ANGSTROMS) OF 1-463 AND 475-622 IN COMPLEX WITH
RP   MANGANESE; GTP AND SUBSTRATES, COFACTOR, AND ACTIVE SITE.
RX   PubMed=23127136; DOI=10.1021/bi301278t;
RA   Johnson T.A., Holyoak T.;
RT   "The Omega-loop lid domain of phosphoenolpyruvate carboxykinase is
RT   essential for catalytic function.";
RL   Biochemistry 51:9547-9559(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH MANGANESE; GTP AND
RP   SUBSTRATE, COFACTOR, AND SUBUNIT.
RX   PubMed=24863970; DOI=10.1016/j.ymgme.2014.04.001;
RA   Adams D.R., Yuan H., Holyoak T., Arajs K.H., Hakimi P., Markello T.C.,
RA   Wolfe L.A., Vilboux T., Burton B.K., Fajardo K.F., Grahame G., Holloman C.,
RA   Sincan M., Smith A.C., Wells G.A., Huang Y., Vega H., Snyder J.P.,
RA   Golas G.A., Tifft C.J., Boerkoel C.F., Hanson R.W., Traynelis S.F.,
RA   Kerr D.S., Gahl W.A.;
RT   "Three rare diseases in one sib pair: RAI1, PCK1, GRIN2B mutations
RT   associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA
RT   receptor glutamate insensitivity.";
RL   Mol. Genet. Metab. 113:161-170(2014).
RN   [15] {ECO:0007744|PDB:4YW8, ECO:0007744|PDB:4YW9, ECO:0007744|PDB:4YWB, ECO:0007744|PDB:4YWD}
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) IN COMPLEX WITH
RP   3-MERCAPTOPICOLINATE; GTP AND MANGANESE, FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, SUBUNIT, AND ACTIVITY REGULATION.
RX   PubMed=26322521; DOI=10.1021/acs.biochem.5b00822;
RA   Balan M.D., Mcleod M.J., Lotosky W.R., Ghaly M., Holyoak T.;
RT   "Inhibition and allosteric regulation of monomeric phosphoenolpyruvate
RT   carboxykinase by 3-mercaptopicolinic acid.";
RL   Biochemistry 54:5878-5887(2015).
RN   [16] {ECO:0007744|PDB:5FH0, ECO:0007744|PDB:5FH1, ECO:0007744|PDB:5FH2, ECO:0007744|PDB:5FH3, ECO:0007744|PDB:5FH4, ECO:0007744|PDB:5FH5}
RP   X-RAY CRYSTALLOGRAPHY (1.49 ANGSTROMS) IN COMPLEX WITH GTP AND MANGANESE,
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR,
RP   SUBUNIT, AND MUTAGENESIS OF GLU-89.
RX   PubMed=26709450; DOI=10.1021/acs.biochem.5b01215;
RA   Johnson T.A., Mcleod M.J., Holyoak T.;
RT   "Utilization of substrate intrinsic binding energy for conformational
RT   change and catalytic function in phosphoenolpyruvate carboxykinase.";
RL   Biochemistry 55:575-587(2016).
RN   [17] {ECO:0007744|PDB:5V95, ECO:0007744|PDB:5V97, ECO:0007744|PDB:5V9F, ECO:0007744|PDB:5V9G, ECO:0007744|PDB:5V9H}
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH GTP AND MANGANESE,
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBUNIT, ACTIVITY REGULATION, AND
RP   MUTAGENESIS OF HIS-477.
RX   PubMed=28345895; DOI=10.1021/acs.biochem.7b00178;
RA   Cui D.S., Broom A., Mcleod M.J., Meiering E.M., Holyoak T.;
RT   "Asymmetric anchoring is required for efficient omega-loop opening and
RT   closing in cytosolic phosphoenolpyruvate carboxykinase.";
RL   Biochemistry 56:2106-2115(2017).
RN   [18] {ECO:0007744|PDB:6P5O}
RP   X-RAY CRYSTALLOGRAPHY (1.49 ANGSTROMS) IN COMPLEX WITH
RP   3-[(CARBOXYMETHYL)THIO]PICOLINATE AND MANGANESE.
RX   PubMed=31461616; DOI=10.1021/acs.biochem.9b00583;
RA   Mcleod M.J., Krismanich A.P., Assoud A., Dmitrienko G.I., Holyoak T.;
RT   "Characterization of 3-[(carboxymethyl)thio]picolinic acid: a novel
RT   inhibitor of phosphoenolpyruvate carboxykinase.";
RL   Biochemistry 58:3918-3926(2019).
CC   -!- FUNCTION: Cytosolic phosphoenolpyruvate carboxykinase that catalyzes
CC       the reversible decarboxylation and phosphorylation of oxaloacetate
CC       (OAA) and acts as the rate-limiting enzyme in gluconeogenesis
CC       (PubMed:26322521, PubMed:26709450, PubMed:28345895, PubMed:30193097,
CC       PubMed:31461616, PubMed:4186849). Regulates cataplerosis and
CC       anaplerosis, the processes that control the levels of metabolic
CC       intermediates in the citric acid cycle (PubMed:30193097). At low
CC       glucose levels, it catalyzes the cataplerotic conversion of
CC       oxaloacetate to phosphoenolpyruvate (PEP), the rate-limiting step in
CC       the metabolic pathway that produces glucose from lactate and other
CC       precursors derived from the citric acid cycle (PubMed:30193097). At
CC       high glucose levels, it catalyzes the anaplerotic conversion of
CC       phosphoenolpyruvate to oxaloacetate (PubMed:30193097). Acts as a
CC       regulator of formation and maintenance of memory CD8(+) T-cells: up-
CC       regulated in these cells, where it generates phosphoenolpyruvate, via
CC       gluconeogenesis (By similarity). The resultant phosphoenolpyruvate
CC       flows to glycogen and pentose phosphate pathway, which is essential for
CC       memory CD8(+) T-cells homeostasis (By similarity). In addition to the
CC       phosphoenolpyruvate carboxykinase activity, also acts as a protein
CC       kinase when phosphorylated at Ser-90: phosphorylation at Ser-90 by AKT1
CC       reduces the binding affinity to oxaloacetate and promotes an atypical
CC       serine protein kinase activity using GTP as donor (By similarity). The
CC       protein kinase activity regulates lipogenesis: upon phosphorylation at
CC       Ser-90, translocates to the endoplasmic reticulum and catalyzes
CC       phosphorylation of INSIG proteins (INSIG1 and INSIG2), thereby
CC       disrupting the interaction between INSIG proteins and SCAP and
CC       promoting nuclear translocation of SREBP proteins (SREBF1/SREBP1 or
CC       SREBF2/SREBP2) and subsequent transcription of downstream lipogenesis-
CC       related genes (By similarity). {ECO:0000250|UniProtKB:P35558,
CC       ECO:0000250|UniProtKB:Q9Z2V4, ECO:0000269|PubMed:26322521,
CC       ECO:0000269|PubMed:26709450, ECO:0000269|PubMed:28345895,
CC       ECO:0000269|PubMed:30193097, ECO:0000269|PubMed:31461616,
CC       ECO:0000269|PubMed:4186849}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP + oxaloacetate = CO2 + GDP + phosphoenolpyruvate;
CC         Xref=Rhea:RHEA:10388, ChEBI:CHEBI:16452, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:37565, ChEBI:CHEBI:58189, ChEBI:CHEBI:58702; EC=4.1.1.32;
CC         Evidence={ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:26709450,
CC         ECO:0000269|PubMed:28345895, ECO:0000269|PubMed:30193097,
CC         ECO:0000269|PubMed:31461616};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10389;
CC         Evidence={ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:30193097};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:10390;
CC         Evidence={ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:28345895,
CC         ECO:0000269|PubMed:30193097};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP + L-seryl-[protein] = GDP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:64020, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:58189, ChEBI:CHEBI:83421;
CC         Evidence={ECO:0000250|UniProtKB:P35558};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64021;
CC         Evidence={ECO:0000250|UniProtKB:P35558};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:17685635, ECO:0000269|PubMed:18197707,
CC         ECO:0000269|PubMed:18772387, ECO:0000269|PubMed:20476774,
CC         ECO:0000269|PubMed:23127136, ECO:0000269|PubMed:24863970,
CC         ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:26709450,
CC         ECO:0000269|PubMed:28345895};
CC       Note=Binds 1 Mn(2+) ion per subunit. {ECO:0000269|PubMed:17685635,
CC       ECO:0000269|PubMed:18197707, ECO:0000269|PubMed:18772387,
CC       ECO:0000269|PubMed:20476774, ECO:0000269|PubMed:23127136,
CC       ECO:0000269|PubMed:24863970, ECO:0000269|PubMed:26322521,
CC       ECO:0000269|PubMed:26709450, ECO:0000269|PubMed:28345895};
CC   -!- ACTIVITY REGULATION: Phosphoenolpyruvate carboxykinase activity is
CC       regulated by acetylation and glucose levels (PubMed:30193097). The
CC       anaplerotic conversion of phosphoenolpyruvate to oxaloacetate is
CC       improved by PCK1 acetylation on Lys-91 (K91ac), Lys-473 (K473ac) and
CC       Lys-521 (K521ac) (PubMed:30193097). High glucose concentrations favor
CC       PCK1 anaplerotic activity by triggering acetylation on Lys-91 (K91ac).
CC       At low glucose levels, SIRT1-mediated deacetylation of Lys-91 promotes
CC       the cataplerotic conversion of oxaloacetate to phosphoenolpyruvate (By
CC       similarity). Phosphoenolpyruvate carboxykinase activity is inhibited by
CC       3-mercaptopicolinate (PubMed:26322521). Phosphoenolpyruvate
CC       carboxykinase activity is inhibited by 3-
CC       [(carboxymethyl)thio]picolinate (CMP), which acts as a competitive
CC       inhibitor at the oxaloacetate/phosphoenolpyruvate-binding site
CC       (PubMed:31461616). Phosphorylation at Ser-90 reduces the binding
CC       affinity to oxaloacetate and converts the enzyme into an atypical
CC       protein kinase using GTP as donor (By similarity).
CC       {ECO:0000250|UniProtKB:P35558, ECO:0000269|PubMed:26322521,
CC       ECO:0000269|PubMed:30193097, ECO:0000269|PubMed:31461616}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=39 uM for oxaloacetate {ECO:0000269|PubMed:30193097};
CC         KM=161 uM for GTP {ECO:0000269|PubMed:30193097};
CC         KM=301 uM for phosphoenolpyruvate {ECO:0000269|PubMed:30193097};
CC         KM=79 uM for GDP {ECO:0000269|PubMed:30193097};
CC         KM=475 uM for phosphoenolpyruvate (for phosphoenolpyruvate
CC         carboxykinase in the backward reaction)
CC         {ECO:0000269|PubMed:26709450};
CC         KM=207 uM for GDP (for phosphoenolpyruvate carboxykinase in the
CC         backward reaction) {ECO:0000269|PubMed:26709450};
CC         KM=435 uM for CO2 (for phosphoenolpyruvate carboxykinase in the
CC         backward reaction) {ECO:0000269|PubMed:26709450};
CC         KM=51 uM for oxaloacetate (for phosphoenolpyruvate carboxykinase in
CC         the forward reaction) {ECO:0000269|PubMed:26709450};
CC         KM=55 uM for GTP (for phosphoenolpyruvate carboxykinase in the
CC         forward reaction) {ECO:0000269|PubMed:26709450};
CC         Note=kcat is 76 sec(-1) with oxaloacetate as substrate
CC         (PubMed:30193097). kcat is 27 sec(-1) with phosphoenolpyruvate as
CC         substrate (PubMed:30193097). kcat is 65 sec(-1) with GTP as substrate
CC         (PubMed:30193097). kcat is 25 sec(-1) with GDP as substrate
CC         (PubMed:30193097). kcat is 52 sec(-1) with phosphoenolpyruvate
CC         carboxykinase in the forward reaction (PubMed:26709450). kcat is 19
CC         sec(-1) with phosphoenolpyruvate carboxykinase in the backward
CC         forward reaction (PubMed:26709450). {ECO:0000269|PubMed:26709450,
CC         ECO:0000269|PubMed:30193097};
CC   -!- PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.
CC       {ECO:0000269|PubMed:30193097}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:17685635,
CC       ECO:0000269|PubMed:18197707, ECO:0000269|PubMed:18772387,
CC       ECO:0000269|PubMed:20476774, ECO:0000269|PubMed:24863970,
CC       ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:26709450,
CC       ECO:0000269|PubMed:31461616}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000305|PubMed:4186849}.
CC       Endoplasmic reticulum {ECO:0000250|UniProtKB:P35558}.
CC       Note=Phosphorylation at Ser-90 promotes translocation to the
CC       endoplasmic reticulum. {ECO:0000250|UniProtKB:P35558}.
CC   -!- INDUCTION: Regulated by cAMP, dexamethasone, glucagon and by insulin.
CC       Dexamthasone, glucagon and cAMP increase levels, insulin decreases
CC       levels. {ECO:0000269|PubMed:18335579, ECO:0000269|PubMed:6096365}.
CC   -!- PTM: Acetylated (PubMed:30193097). Lysine acetylation by p300/EP300 is
CC       increased on high glucose conditions and promotes ubiquitination by
CC       UBR5; acetylation is enhanced in the presence of BAG6. Deacetylated by
CC       SIRT2. Deacetylation of Lys-91 is carried out by SIRT1 and depends on
CC       PCK1 phosphorylation levels (By similarity).
CC       {ECO:0000250|UniProtKB:P35558, ECO:0000269|PubMed:30193097}.
CC   -!- PTM: Phosphorylated in a GSK3B-mediated pathway; phosphorylation
CC       affects the efficiency of SIRT1-mediated deacetylation, and regulates
CC       PCK1 ubiquitination and degradation (PubMed:30193097). Phosphorylation
CC       at Ser-90 by AKT1 reduces the binding affinity to oxaloacetate and
CC       promotes the protein kinase activity: phosphorylated PCK1 translocates
CC       to the endoplasmic reticulum, where it phosphorylates INSIG1 and INSIG2
CC       (By similarity). {ECO:0000250|UniProtKB:P35558,
CC       ECO:0000269|PubMed:30193097}.
CC   -!- PTM: Ubiquitination by UBR5 leads to proteasomal degradation.
CC       {ECO:0000250|UniProtKB:P35558}.
CC   -!- MISCELLANEOUS: In eukaryotes there are two isozymes: a cytoplasmic one
CC       and a mitochondrial one. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the phosphoenolpyruvate carboxykinase [GTP]
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; K03248; AAC98698.1; -; Genomic_DNA.
DR   EMBL; K03243; AAC98698.1; JOINED; Genomic_DNA.
DR   EMBL; K03244; AAC98698.1; JOINED; Genomic_DNA.
DR   EMBL; K03245; AAC98698.1; JOINED; Genomic_DNA.
DR   EMBL; K03246; AAC98698.1; JOINED; Genomic_DNA.
DR   EMBL; K03247; AAC98698.1; JOINED; Genomic_DNA.
DR   EMBL; BC081900; AAH81900.1; -; mRNA.
DR   PIR; A23927; QYRTGP.
DR   RefSeq; NP_942075.1; NM_198780.3.
DR   PDB; 2QEW; X-ray; 1.80 A; A=1-622.
DR   PDB; 2QEY; X-ray; 1.90 A; A=1-622.
DR   PDB; 2QF1; X-ray; 1.80 A; A=1-622.
DR   PDB; 2QF2; X-ray; 1.65 A; A/B=1-622.
DR   PDB; 2RK7; X-ray; 1.90 A; A/B=1-622.
DR   PDB; 2RK8; X-ray; 2.00 A; A/B=1-622.
DR   PDB; 2RKA; X-ray; 1.95 A; A/C=1-622.
DR   PDB; 2RKD; X-ray; 1.90 A; A=1-622.
DR   PDB; 2RKE; X-ray; 1.80 A; A=1-622.
DR   PDB; 3DT2; X-ray; 1.50 A; A=1-622.
DR   PDB; 3DT4; X-ray; 1.45 A; A/C=1-622.
DR   PDB; 3DT7; X-ray; 1.50 A; A/B=1-622.
DR   PDB; 3DTB; X-ray; 1.30 A; A/B=1-622.
DR   PDB; 3MOE; X-ray; 1.25 A; A=1-622.
DR   PDB; 3MOF; X-ray; 1.75 A; A/B=1-622.
DR   PDB; 3MOH; X-ray; 2.10 A; A/B=1-622.
DR   PDB; 4GMM; X-ray; 1.74 A; A=1-463, A=475-622.
DR   PDB; 4GMU; X-ray; 1.20 A; A=1-463, A=475-622.
DR   PDB; 4GMW; X-ray; 1.75 A; A=1-463, A=475-622.
DR   PDB; 4GMZ; X-ray; 2.05 A; A=1-463, A=475-622.
DR   PDB; 4GNL; X-ray; 1.70 A; A=1-463, A=475-622.
DR   PDB; 4GNM; X-ray; 1.50 A; A=1-463, A=475-622.
DR   PDB; 4GNO; X-ray; 1.50 A; A=1-463, A=475-622.
DR   PDB; 4GNP; X-ray; 1.74 A; A=1-463, A=475-622.
DR   PDB; 4GNQ; X-ray; 1.40 A; A=1-463, A=475-622.
DR   PDB; 4OX2; X-ray; 2.00 A; A/B=1-622.
DR   PDB; 4YW8; X-ray; 1.55 A; A=1-622.
DR   PDB; 4YW9; X-ray; 1.40 A; A=1-622.
DR   PDB; 4YWB; X-ray; 1.50 A; A/C=1-622.
DR   PDB; 4YWD; X-ray; 2.10 A; A=1-622.
DR   PDB; 5FH0; X-ray; 1.60 A; A=1-622.
DR   PDB; 5FH1; X-ray; 1.55 A; A=1-622.
DR   PDB; 5FH2; X-ray; 1.49 A; A=1-622.
DR   PDB; 5FH3; X-ray; 1.60 A; A=1-622.
DR   PDB; 5FH4; X-ray; 1.49 A; A=1-622.
DR   PDB; 5FH5; X-ray; 1.55 A; A=1-622.
DR   PDB; 5V95; X-ray; 2.30 A; A=1-622.
DR   PDB; 5V97; X-ray; 1.80 A; A=1-622.
DR   PDB; 5V9F; X-ray; 2.05 A; A=1-622.
DR   PDB; 5V9G; X-ray; 1.95 A; A=1-622.
DR   PDB; 5V9H; X-ray; 2.15 A; A/B=1-622.
DR   PDB; 6P5O; X-ray; 1.49 A; A=1-622.
DR   PDB; 6YI9; X-ray; 1.75 A; A=1-622.
DR   PDB; 7L36; X-ray; 1.84 A; A=1-622.
DR   PDB; 7L3M; X-ray; 2.07 A; A=1-622.
DR   PDB; 7L3V; X-ray; 1.98 A; A=1-622.
DR   PDBsum; 2QEW; -.
DR   PDBsum; 2QEY; -.
DR   PDBsum; 2QF1; -.
DR   PDBsum; 2QF2; -.
DR   PDBsum; 2RK7; -.
DR   PDBsum; 2RK8; -.
DR   PDBsum; 2RKA; -.
DR   PDBsum; 2RKD; -.
DR   PDBsum; 2RKE; -.
DR   PDBsum; 3DT2; -.
DR   PDBsum; 3DT4; -.
DR   PDBsum; 3DT7; -.
DR   PDBsum; 3DTB; -.
DR   PDBsum; 3MOE; -.
DR   PDBsum; 3MOF; -.
DR   PDBsum; 3MOH; -.
DR   PDBsum; 4GMM; -.
DR   PDBsum; 4GMU; -.
DR   PDBsum; 4GMW; -.
DR   PDBsum; 4GMZ; -.
DR   PDBsum; 4GNL; -.
DR   PDBsum; 4GNM; -.
DR   PDBsum; 4GNO; -.
DR   PDBsum; 4GNP; -.
DR   PDBsum; 4GNQ; -.
DR   PDBsum; 4OX2; -.
DR   PDBsum; 4YW8; -.
DR   PDBsum; 4YW9; -.
DR   PDBsum; 4YWB; -.
DR   PDBsum; 4YWD; -.
DR   PDBsum; 5FH0; -.
DR   PDBsum; 5FH1; -.
DR   PDBsum; 5FH2; -.
DR   PDBsum; 5FH3; -.
DR   PDBsum; 5FH4; -.
DR   PDBsum; 5FH5; -.
DR   PDBsum; 5V95; -.
DR   PDBsum; 5V97; -.
DR   PDBsum; 5V9F; -.
DR   PDBsum; 5V9G; -.
DR   PDBsum; 5V9H; -.
DR   PDBsum; 6P5O; -.
DR   PDBsum; 6YI9; -.
DR   PDBsum; 7L36; -.
DR   PDBsum; 7L3M; -.
DR   PDBsum; 7L3V; -.
DR   AlphaFoldDB; P07379; -.
DR   SMR; P07379; -.
DR   BioGRID; 263330; 1.
DR   STRING; 10116.ENSRNOP00000030913; -.
DR   BindingDB; P07379; -.
DR   ChEMBL; CHEMBL1075234; -.
DR   iPTMnet; P07379; -.
DR   PhosphoSitePlus; P07379; -.
DR   jPOST; P07379; -.
DR   PaxDb; 10116-ENSRNOP00000030913; -.
DR   Ensembl; ENSRNOT00000031586.7; ENSRNOP00000030913.4; ENSRNOG00000028616.7.
DR   Ensembl; ENSRNOT00055001468; ENSRNOP00055001188; ENSRNOG00055000874.
DR   GeneID; 362282; -.
DR   KEGG; rno:362282; -.
DR   AGR; RGD:3267; -.
DR   CTD; 5105; -.
DR   RGD; 3267; Pck1.
DR   eggNOG; KOG3749; Eukaryota.
DR   GeneTree; ENSGT00390000001912; -.
DR   HOGENOM; CLU_028872_1_0_1; -.
DR   InParanoid; P07379; -.
DR   OMA; GPTNNWV; -.
DR   OrthoDB; 5471652at2759; -.
DR   PhylomeDB; P07379; -.
DR   TreeFam; TF314402; -.
DR   BRENDA; 4.1.1.32; 5301.
DR   Reactome; R-RNO-70263; Gluconeogenesis.
DR   SABIO-RK; P07379; -.
DR   UniPathway; UPA00138; -.
DR   EvolutionaryTrace; P07379; -.
DR   PRO; PR:P07379; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Bgee; ENSRNOG00000028616; Expressed in kidney and 17 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0031406; F:carboxylic acid binding; IDA:BHF-UCL.
DR   GO; GO:0019003; F:GDP binding; IDA:RGD.
DR   GO; GO:0005525; F:GTP binding; IDA:BHF-UCL.
DR   GO; GO:0000287; F:magnesium ion binding; ISS:BHF-UCL.
DR   GO; GO:0030145; F:manganese ion binding; IDA:BHF-UCL.
DR   GO; GO:0004550; F:nucleoside diphosphate kinase activity; EXP:Reactome.
DR   GO; GO:0004613; F:phosphoenolpyruvate carboxykinase (GTP) activity; IDA:UniProtKB.
DR   GO; GO:0004611; F:phosphoenolpyruvate carboxykinase activity; IDA:RGD.
DR   GO; GO:0106264; F:protein serine kinase activity (using GTP as donor); ISS:UniProtKB.
DR   GO; GO:0071474; P:cellular hyperosmotic response; IEP:RGD.
DR   GO; GO:0071475; P:cellular hyperosmotic salinity response; IEP:RGD.
DR   GO; GO:0071476; P:cellular hypotonic response; IEP:RGD.
DR   GO; GO:0071477; P:cellular hypotonic salinity response; IEP:RGD.
DR   GO; GO:0071320; P:cellular response to cAMP; IEP:RGD.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IBA:GO_Central.
DR   GO; GO:0071332; P:cellular response to fructose stimulus; IEP:RGD.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; IEP:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEP:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:RGD.
DR   GO; GO:1904628; P:cellular response to phorbol 13-acetate 12-myristate; IEP:RGD.
DR   GO; GO:0051365; P:cellular response to potassium ion starvation; ISO:RGD.
DR   GO; GO:0097403; P:cellular response to raffinose; IEP:RGD.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEP:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:RGD.
DR   GO; GO:0006094; P:gluconeogenesis; IDA:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IDA:BHF-UCL.
DR   GO; GO:0006006; P:glucose metabolic process; IMP:BHF-UCL.
DR   GO; GO:0046166; P:glyceraldehyde-3-phosphate biosynthetic process; ISO:RGD.
DR   GO; GO:0046327; P:glycerol biosynthetic process from pyruvate; IDA:BHF-UCL.
DR   GO; GO:0070365; P:hepatocyte differentiation; IBA:GO_Central.
DR   GO; GO:0006629; P:lipid metabolic process; ISO:RGD.
DR   GO; GO:0006107; P:oxaloacetate metabolic process; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; ISO:RGD.
DR   GO; GO:0043382; P:positive regulation of memory T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0019543; P:propionate catabolic process; IBA:GO_Central.
DR   GO; GO:0046890; P:regulation of lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0009617; P:response to bacterium; ISO:RGD.
DR   GO; GO:0032868; P:response to insulin; ISS:BHF-UCL.
DR   GO; GO:0070741; P:response to interleukin-6; IEP:RGD.
DR   GO; GO:0033993; P:response to lipid; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:1904640; P:response to methionine; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0042594; P:response to starvation; IBA:GO_Central.
DR   GO; GO:0072350; P:tricarboxylic acid metabolic process; ISO:RGD.
DR   CDD; cd00819; PEPCK_GTP; 1.
DR   Gene3D; 3.90.228.20; -; 1.
DR   Gene3D; 3.40.449.10; Phosphoenolpyruvate Carboxykinase, domain 1; 1.
DR   Gene3D; 2.170.8.10; Phosphoenolpyruvate Carboxykinase, domain 2; 1.
DR   HAMAP; MF_00452; PEPCK_GTP; 1.
DR   InterPro; IPR018091; PEP_carboxykin_GTP_CS.
DR   InterPro; IPR013035; PEP_carboxykinase_C.
DR   InterPro; IPR008209; PEP_carboxykinase_GTP.
DR   InterPro; IPR035077; PEP_carboxykinase_GTP_C.
DR   InterPro; IPR035078; PEP_carboxykinase_GTP_N.
DR   InterPro; IPR008210; PEP_carboxykinase_N.
DR   PANTHER; PTHR11561; PHOSPHOENOLPYRUVATE CARBOXYKINASE; 1.
DR   PANTHER; PTHR11561:SF19; PHOSPHOENOLPYRUVATE CARBOXYKINASE, CYTOSOLIC [GTP]; 1.
DR   Pfam; PF00821; PEPCK_GTP; 1.
DR   Pfam; PF17297; PEPCK_N; 1.
DR   PIRSF; PIRSF001348; PEP_carboxykinase_GTP; 1.
DR   SUPFAM; SSF68923; PEP carboxykinase N-terminal domain; 1.
DR   SUPFAM; SSF53795; PEP carboxykinase-like; 1.
DR   PROSITE; PS00505; PEPCK_GTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Decarboxylase;
KW   Direct protein sequencing; Endoplasmic reticulum; Gluconeogenesis;
KW   GTP-binding; Kinase; Lyase; Manganese; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Transferase; Ubl conjugation.
FT   CHAIN           1..622
FT                   /note="Phosphoenolpyruvate carboxykinase, cytosolic [GTP]"
FT                   /id="PRO_0000103630"
FT   REGION          457..487
FT                   /note="Omega-loop"
FT                   /evidence="ECO:0000269|PubMed:28345895"
FT   ACT_SITE        288
FT                   /evidence="ECO:0000269|PubMed:23127136,
FT                   ECO:0000269|PubMed:2909519"
FT   BINDING         87
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:18772387, ECO:0000269|PubMed:20476774,
FT                   ECO:0000269|PubMed:23127136, ECO:0000269|PubMed:24863970"
FT   BINDING         235..237
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:18197707,
FT                   ECO:0000269|PubMed:18772387, ECO:0000269|PubMed:20476774,
FT                   ECO:0000269|PubMed:23127136, ECO:0000269|PubMed:24863970"
FT   BINDING         244
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:18197707, ECO:0000269|PubMed:18772387,
FT                   ECO:0000269|PubMed:20476774, ECO:0000269|PubMed:23127136,
FT                   ECO:0000269|PubMed:24863970, ECO:0000269|PubMed:26322521,
FT                   ECO:0000269|PubMed:26709450, ECO:0000269|PubMed:28345895,
FT                   ECO:0000269|PubMed:31461616, ECO:0007744|PDB:4YW9,
FT                   ECO:0007744|PDB:5FH0, ECO:0007744|PDB:5FH1,
FT                   ECO:0007744|PDB:5FH2, ECO:0007744|PDB:5FH3,
FT                   ECO:0007744|PDB:5FH4, ECO:0007744|PDB:5FH5,
FT                   ECO:0007744|PDB:5V97, ECO:0007744|PDB:5V9F,
FT                   ECO:0007744|PDB:5V9G, ECO:0007744|PDB:6P5O"
FT   BINDING         264
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:18197707, ECO:0000269|PubMed:18772387,
FT                   ECO:0000269|PubMed:20476774, ECO:0000269|PubMed:23127136,
FT                   ECO:0000269|PubMed:24863970, ECO:0000269|PubMed:26322521,
FT                   ECO:0000269|PubMed:26709450, ECO:0000269|PubMed:28345895,
FT                   ECO:0000269|PubMed:31461616, ECO:0007744|PDB:4YW9,
FT                   ECO:0007744|PDB:5FH0, ECO:0007744|PDB:5FH1,
FT                   ECO:0007744|PDB:5FH2, ECO:0007744|PDB:5FH3,
FT                   ECO:0007744|PDB:5FH4, ECO:0007744|PDB:5FH5,
FT                   ECO:0007744|PDB:5V97, ECO:0007744|PDB:5V9F,
FT                   ECO:0007744|PDB:5V9G, ECO:0007744|PDB:6P5O"
FT   BINDING         286
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:18197707, ECO:0000269|PubMed:18772387,
FT                   ECO:0000269|PubMed:20476774, ECO:0000269|PubMed:23127136,
FT                   ECO:0000269|PubMed:24863970"
FT   BINDING         287..292
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:18772387, ECO:0000269|PubMed:20476774,
FT                   ECO:0000269|PubMed:23127136, ECO:0000269|PubMed:24863970,
FT                   ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:26709450,
FT                   ECO:0000269|PubMed:28345895, ECO:0007744|PDB:4YW9,
FT                   ECO:0007744|PDB:5FH0, ECO:0007744|PDB:5FH1,
FT                   ECO:0007744|PDB:5FH2, ECO:0007744|PDB:5FH3,
FT                   ECO:0007744|PDB:5FH4, ECO:0007744|PDB:5V97,
FT                   ECO:0007744|PDB:5V9F, ECO:0007744|PDB:5V9G"
FT   BINDING         311
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:18197707, ECO:0000269|PubMed:18772387,
FT                   ECO:0000269|PubMed:20476774, ECO:0000269|PubMed:23127136,
FT                   ECO:0000269|PubMed:24863970, ECO:0000269|PubMed:26322521,
FT                   ECO:0000269|PubMed:26709450, ECO:0000269|PubMed:28345895,
FT                   ECO:0000269|PubMed:31461616, ECO:0007744|PDB:4YW9,
FT                   ECO:0007744|PDB:5FH0, ECO:0007744|PDB:5FH1,
FT                   ECO:0007744|PDB:5FH2, ECO:0007744|PDB:5FH3,
FT                   ECO:0007744|PDB:5FH4, ECO:0007744|PDB:5FH5,
FT                   ECO:0007744|PDB:5V97, ECO:0007744|PDB:5V9F,
FT                   ECO:0007744|PDB:5V9G, ECO:0007744|PDB:6P5O"
FT   BINDING         403..405
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:18197707,
FT                   ECO:0000269|PubMed:18772387, ECO:0000269|PubMed:20476774,
FT                   ECO:0000269|PubMed:23127136, ECO:0000269|PubMed:24863970"
FT   BINDING         405
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:20476774, ECO:0000269|PubMed:23127136,
FT                   ECO:0000269|PubMed:24863970, ECO:0000269|PubMed:26322521,
FT                   ECO:0000269|PubMed:26709450, ECO:0000269|PubMed:28345895,
FT                   ECO:0007744|PDB:4YW9, ECO:0007744|PDB:5FH0,
FT                   ECO:0007744|PDB:5FH1, ECO:0007744|PDB:5FH2,
FT                   ECO:0007744|PDB:5FH3, ECO:0007744|PDB:5FH4,
FT                   ECO:0007744|PDB:5V97, ECO:0007744|PDB:5V9F,
FT                   ECO:0007744|PDB:5V9G"
FT   BINDING         436
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:18772387, ECO:0000269|PubMed:20476774,
FT                   ECO:0000269|PubMed:23127136, ECO:0000269|PubMed:24863970,
FT                   ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:26709450,
FT                   ECO:0000269|PubMed:28345895, ECO:0007744|PDB:4YW9,
FT                   ECO:0007744|PDB:5FH0, ECO:0007744|PDB:5FH1,
FT                   ECO:0007744|PDB:5FH2, ECO:0007744|PDB:5FH3,
FT                   ECO:0007744|PDB:5FH4, ECO:0007744|PDB:5V97,
FT                   ECO:0007744|PDB:5V9F, ECO:0007744|PDB:5V9G"
FT   BINDING         530..533
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:17685635,
FT                   ECO:0000269|PubMed:18772387, ECO:0000269|PubMed:20476774,
FT                   ECO:0000269|PubMed:23127136, ECO:0000269|PubMed:24863970,
FT                   ECO:0000269|PubMed:26322521, ECO:0000269|PubMed:26709450,
FT                   ECO:0000269|PubMed:28345895, ECO:0007744|PDB:4YW9,
FT                   ECO:0007744|PDB:5FH0, ECO:0007744|PDB:5FH1,
FT                   ECO:0007744|PDB:5FH2, ECO:0007744|PDB:5FH3,
FT                   ECO:0007744|PDB:5FH4, ECO:0007744|PDB:5V97,
FT                   ECO:0007744|PDB:5V9F, ECO:0007744|PDB:5V9G"
FT   MOD_RES         19
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         70
FT                   /note="N6-acetyllysine; by p300/EP300"
FT                   /evidence="ECO:0000250|UniProtKB:P35558"
FT   MOD_RES         71
FT                   /note="N6-acetyllysine; by p300/EP300"
FT                   /evidence="ECO:0000250|UniProtKB:P35558"
FT   MOD_RES         90
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P35558"
FT   MOD_RES         91
FT                   /note="N6-acetyllysine; by p300/EP300"
FT                   /evidence="ECO:0000250|UniProtKB:P35558,
FT                   ECO:0000269|PubMed:30193097"
FT   MOD_RES         118
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         178
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q16822"
FT   MOD_RES         286
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q16822"
FT   MOD_RES         473
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:30193097"
FT   MOD_RES         521
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:30193097"
FT   MOD_RES         524
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:30193097"
FT   MOD_RES         594
FT                   /note="N6-acetyllysine; by p300/EP300"
FT                   /evidence="ECO:0000250|UniProtKB:P35558"
FT   MUTAGEN         89
FT                   /note="E->A,D,Q: Abolished phosphoenolpyruvate
FT                   carboxykinase activity; decreased affinity for
FT                   oxaloacetate."
FT                   /evidence="ECO:0000269|PubMed:26709450"
FT   MUTAGEN         90
FT                   /note="S->A: Decreased phosphorylation and increased
FT                   acetylation levels."
FT                   /evidence="ECO:0000269|PubMed:30193097"
FT   MUTAGEN         91
FT                   /note="K->Q: 3-fold decrease of affinity for
FT                   phosphoenolpyruvate."
FT                   /evidence="ECO:0000269|PubMed:30193097"
FT   MUTAGEN         477
FT                   /note="H->R: Destabilization of the closed state of the
FT                   omega-loop, resulting in decreased capture rates for the
FT                   weaker binding substrates associated with catalysis in the
FT                   phosphoenolpyruvate to oxaloacetate direction."
FT                   /evidence="ECO:0000269|PubMed:28345895"
FT   STRAND          5..9
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           12..14
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          15..18
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           20..22
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           25..38
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          40..45
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           50..62
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          65..69
FT                   /evidence="ECO:0007829|PDB:4GNQ"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          76..78
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          84..86
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           89..91
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          92..95
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           99..102
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          107..109
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           119..127
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   TURN            131..134
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          137..148
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          155..162
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           164..173
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          174..177
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           178..184
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          190..195
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           214..216
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          218..222
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          227..232
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           236..239
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           242..248
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           249..258
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          261..264
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          266..271
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          277..283
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          286..289
FT                   /evidence="ECO:0007829|PDB:6YI9"
FT   HELIX           290..294
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          304..311
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          313..317
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          323..326
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          330..335
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   TURN            341..343
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           345..350
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          356..359
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          361..363
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          388..391
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          395..397
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          405..409
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           410..412
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   TURN            418..421
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          426..434
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          438..440
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          443..446
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           450..458
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          461..463
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          466..469
FT                   /evidence="ECO:0007829|PDB:3DT4"
FT   STRAND          475..477
FT                   /evidence="ECO:0007829|PDB:3MOE"
FT   HELIX           479..481
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   TURN            483..485
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           490..499
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           500..502
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          510..514
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          521..523
FT                   /evidence="ECO:0007829|PDB:2RKD"
FT   STRAND          525..527
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           530..533
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           534..544
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          550..553
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   STRAND          556..559
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   TURN            561..563
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   TURN            567..569
FT                   /evidence="ECO:0007829|PDB:5FH4"
FT   HELIX           574..578
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           582..599
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           601..603
FT                   /evidence="ECO:0007829|PDB:4GMU"
FT   HELIX           606..620
FT                   /evidence="ECO:0007829|PDB:4GMU"
SQ   SEQUENCE   622 AA;  69416 MW;  F800F73F8F127B04 CRC64;
     MPPQLHNGLD FSAKVIQGSL DSLPQEVRKF VEGNAQLCQP EYIHICDGSE EEYGRLLAHM
     QEEGVIRKLK KYDNCWLALT DPRDVARIES KTVIITQEQR DTVPIPKSGQ SQLGRWMSEE
     DFEKAFNARF PGCMKGRTMY VIPFSMGPLG SPLAKIGIEL TDSPYVVASM RIMTRMGTSV
     LEALGDGEFI KCLHSVGCPL PLKKPLVNNW ACNPELTLIA HLPDRREIIS FGSGYGGNSL
     LGKKCFALRI ASRLAKEEGW LAEHMLILGI TNPEGKKKYL AAAFPSACGK TNLAMMNPTL
     PGWKVECVGD DIAWMKFDAQ GNLRAINPEN GFFGVAPGTS VKTNPNAIKT IQKNTIFTNV
     AETSDGGVYW EGIDEPLAPG VTITSWKNKE WRPQDEEPCA HPNSRFCTPA SQCPIIDPAW
     ESPEGVPIEG IIFGGRRPAG VPLVYEALSW QHGVFVGAAM RSEATAAAEH KGKVIMHDPF
     AMRPFFGYNF GKYLAHWLSM AHRPAAKLPK IFHVNWFRKD KNGKFLWPGF GENSRVLEWM
     FGRIEGEDSA KLTPIGYVPK EDALNLKGLG DVNVEELFGI SKEFWEKEVE EIDKYLEDQV
     NADLPYEIER ELRALKQRIS QM
//
